Skip to main content
. Author manuscript; available in PMC: 2014 Apr 2.
Published in final edited form as: Breast Cancer Res Treat. 2013 Apr 2;138(3):807–816. doi: 10.1007/s10549-013-2504-3

Figure 2. Kaplan Meier plot of associations between ESR1 rs9322336 SNP and aromatase inhibitor (AI) discontinuation because of AI-associated musculoskeletal syndrome.

Figure 2

Percentage of subjects continuing AI therapy are given over time for subjects with CC, TC, or TT genotypes. (A) Letrozole-treated subjects. (B) Exemestane-treated subjects. Analysis was performed using a recessive statistical model, and P values were adjusted for age > 55, AI medication, and prior taxane therapy.